LUCY
Innovative Eyewear, Inc.
NASDAQ · Healthcare · Medical - Instruments & Supplies · US
$0.93
+2.73%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 3.4M | 2.7M | 1.6M | 1.2M | 659.8K |
| Cost of Revenue | 2.6M | 2.1M | 1.4M | 1.3M | 716.1K |
| Gross Profit | 777.5K | 567.5K | 215.2K | (119.3K) | (56.3K) |
| Operating Expenses | |||||
| R&D Expense | 526.8K | 725.4M | 819.4K | 662.2K | 524.7K |
| SG&A Expense | 7.0M | 2.3B | 7.2M | 5.9M | 4.9M |
| General & Admin Expense | 5.6M | 5.2B | 4.5M | 3.9M | 2.8M |
| Selling & Marketing Expense | 1.4M | (3.0B) | 2.7M | 2.0M | 2.1M |
| Other Expenses | 1.7M | (3.0B) | 140.0K | 140.0K | 140.0K |
| Total Operating Expenses | 9.3M | 9.1M | 8.1M | 6.7M | 5.5M |
| Cost and Expenses | 11.9M | 11.2M | 9.6M | 8.0M | 6.2M |
| Operating Income (EBIT) | (8.5M) | (8.5M) | (7.9M) | (6.9M) | (5.6M) |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | 3.0K | 105.2K |
| Net Interest Income | — | — | — | (3.0K) | (105.2K) |
| Other Non-Op Income/Expense | 810.2K | 903.8K | 157.2K | 192.1K | (105.2K) |
| Non-Operating Income (excl Interest) | (2.5M) | (903.8K) | (157.2K) | (195.2K) | — |
| EBT (Pre-Tax Income) | (7.7M) | (7.6M) | (7.8M) | (6.7M) | (5.7M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (7.7M) | (7.6M) | (7.8M) | (6.7M) | (5.7M) |
| Earnings from Cont. Ops | (7.7M) | (7.6M) | (7.8M) | (6.7M) | (5.7M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (7.7M) | (7.6M) | (7.8M) | (6.7M) | (5.7M) |
| Per Share | |||||
| Basic EPS | ($1.35) | ($1.90) | ($5.19) | ($12.67) | ($17.41) |
| Diluted EPS | ($1.35) | ($1.90) | ($5.19) | ($12.67) | ($17.41) |
| Revenue Per Share | $0.53 | $0.67 | $1.09 | $2.19 | $2.02 |
| Shares | |||||
| Basic Shares Outstanding | 6.4M | 4.0M | 1.5M | 525800 | 326448 |
| Diluted Shares Outstanding | 6.4M | 4.0M | 1.5M | 525800 | 326448 |
| Profitability Metrics | |||||
| EBITDA | (7.6M) | (7.5M) | (7.6M) | (6.6M) | (5.5M) |
| D&A | 120.0K | 135.3K | 149.4K | 85.3K | 32.6K |
| EBIT | (7.7M) | (7.6M) | (7.8M) | (6.7M) | (5.6M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026